Randomized, parallel, comparison, double-blind efficacy and safety study of Aprovel (irbesartan) versus placebo in Chinese patients with hypertensive type II diabetic patients with microalbuminuria

Trial Profile

Randomized, parallel, comparison, double-blind efficacy and safety study of Aprovel (irbesartan) versus placebo in Chinese patients with hypertensive type II diabetic patients with microalbuminuria

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2014

At a glance

  • Drugs Irbesartan (Primary)
  • Indications Diabetic nephropathies; Hypertension; Proteinuria
  • Focus Therapeutic Use
  • Acronyms PRIME
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top